SBI Securities Co. Ltd. Takes Position in Clene Inc. (NASDAQ:CLNN)

SBI Securities Co. Ltd. acquired a new stake in shares of Clene Inc. (NASDAQ:CLNN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 13,025 shares of the company’s stock, valued at approximately $69,000. SBI Securities Co. Ltd. owned 0.16% of Clene at the end of the most recent reporting period.

Separately, Parsons Capital Management Inc. RI bought a new position in Clene during the 4th quarter valued at $194,000. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Stock Up 1.1 %

Shares of NASDAQ CLNN opened at $4.58 on Monday. Clene Inc. has a 12 month low of $3.82 and a 12 month high of $10.20. The company has a market cap of $38.13 million, a price-to-earnings ratio of -0.87 and a beta of 0.27. The business has a fifty day simple moving average of $4.76 and a 200-day simple moving average of $5.01.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Benchmark cut their price objective on Clene from $90.00 to $84.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Canaccord Genuity Group dropped their price target on shares of Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a research report on Tuesday, February 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Clene in a report on Tuesday, February 25th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $55.25.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.